SGO Annual Meeting | Conference

Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian Cancer

March 28th 2023

Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.

Dr Mirza on Dostarlimab Plus Chemotherapy in Endometrial Cancer

March 28th 2023

Mansoor Raza Mirza, MD, discusses findings from the phase 3 RUBY trial in patients with endometrial cancer.

Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian Cancer

March 27th 2023

Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.

Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal Resection

March 27th 2023

Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.

Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer

March 27th 2023

Botensilimab in combination with balstilimab induced durable responses in patients with resistant/refractory ovarian cancer.

Lenvatinib Plus Pembrolizumab Produces Deep, Sustained Responses in Advanced Endometrial Cancer

March 27th 2023

The combination of lenvatinib plus pembrolizumab produced deep, durable tumor responses in both all-comer and mismatch repair–proficient (pMRR) populations of patients with advanced endometrial cancer, according to data from the phase 3 Study 309/KEYNOTE-775 trial.

Toripalimab Plus Bevacizumab/Chemotherapy Generates Responses in Refractory, Recurrent, or Metastatic Cervical Cancer

March 27th 2023

The combination of toripalimab, bevacizumab, and platinum-based chemotherapy elicited responses in patients with refractory, recurrent or metastatic cervical cancer.

Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian Cancer

March 27th 2023

Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.

Tolerability Hinders Adavosertib Activity in Recurrent or Persistent Uterine Serous Carcinoma

March 27th 2023

Treatment with the oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma who previously received platinum-based chemotherapy.

Durvalumab Plus Tremelimumab and Hypofractionated Radiotherapy Shows Early Promise in Gynecologic Cancers

March 27th 2023

The combination of durvalumab, tremelimumab, and hypofractionated radiotherapy demonstrated early tolerability in patients with gynecologic malignancies and elicited objective responses in those with PD-L1–high tumors.

Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2023

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

Dr Matulonis on Second-line Maintenance Therapy With Niraparib in Ovarian Cancer

March 27th 2023

Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.

Carolina Frailty Index Score Shows Utility in Ovarian Cancer Setting

March 27th 2023

Women with ovarian cancer may be effectively assessed for frailty status via the Carolina Frailty Index Score.

Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer

March 27th 2023

The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.

Post-Hoc Analysis Shows PFS Benefit of Maintenance Niraparib Not Affected by Dose Modifications in Ovarian Cancer

March 27th 2023

The use of an individualized starting dose and dose modifications due to treatment-emergent adverse effects did not impact the efficacy of maintenance niraparib in patients with newly diagnosed ovarian cancer, irrespective of BRCA mutation status.

Neoadjuvant Durvalumab/Tremelimumab Plus Chemo Meets PFS End Point in Advanced Ovarian Cancer

March 27th 2023

Neoadjuvant treatment with the combination of durvalumab plus tremelimumab and chemotherapy elicited a promising 12-month progression-free survival rate in patients with advanced-stage ovarian cancer.

Similar Total Scores Are Observed With GCLQ and LELSQ in Assessing Patients With Endometrial Cancer for Lymphedema

March 26th 2023

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed moderate to substantial agreement across different cutoff points.

Long-Term HRQOL Remains Unimpaired With HIPEC Plus Cytoreductive Surgery in Newly Diagnosed Ovarian Cancer

March 26th 2023

Administration of hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not have a negative impact on health-related quality of life compared with cytoreductive surgery alone in patients with newly diagnosed ovarian cancer, according to findings from a phase 2 trial.

Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer

March 22nd 2022

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Dr. Slomovitz on the Key Objectives of the KEYNOTE-B21 Trial in High-Risk Endometrial Cancer

March 22nd 2022

Brian M. Slomovitz, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.